HopeStage
Back to all studies
RecruitingNCT05027919

Opioid withdrawal symptoms during a supervised medication taper

About this titleRead the official source — NCT05027919
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
BaltimoreSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: December 1, 2021
Recruitment status
Recruiting
Enrollment listed in the registry
60
Sponsor
University of Maryland, Baltimore
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05027919
Official title
Show the full official title

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Recruitment & locations

Currently recruiting

Baltimore

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Does this study involve medication?

Yes. The study involves medication, including Hydromorphone, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment and Lofexidine.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies